workshops organized to date
Regulatory science is the science of developing and validating new standards and tools to evaluate and assess the benefit/risk of medicinal products, thereby facilitating sound and transparent regulatory decision making. It differs from 'classical' academic sciences in the sense that questions posed often originate from government bodies, industry, medical professionals, patient organizations, and NGOs. Those questions focus on increasing the efficiency of the regulatory system, in order to improve its effectiveness on the basis of scientific research results.
RSNN is a network of experts from industry, academia, government bodies, and the broader regulatory science field. Our mission is to advance an efficient and effective regulatory system that supports medicines development, marketing authorization, access, and appropriate use of medicines. RSNN shares and disseminates knowledge among all stakeholders and sets the agenda for further research.
RSNN was founded on October 5, 2015, during the FIGON Dutch Medicines Days. It was initiated by the Medicines Evaluation Board (MEB), the TI Pharma Escher project, and the Dutch Society of Pharmaceutical Medicine, in order to consolidate and strengthen national research networks in the field of regulatory science.
Coordinating inclusive dialogue towards impactful output
In 2018, Lygature coordinated strategic discussions that led to RSNN becoming a partnership. As one of the four partners, Lygature provides the necessary managerial and scientific expertise, ensuring inclusive discussions and meaningful outputs. Activities include:
- Coordination, program management and communications. Lygature handles day-to-day operations of the RSNN including administrative, financial, and communications activities. Lygature provides strategic advice to the RSNN board and helps to define future directions.
- Stakeholder management. Lygature is responsible for the inclusion and involvement of relevant stakeholders in the RSNN. This includes identifying opportunities for future support of the network’s activities (e.g. through financial and in-kind contributions).
- Scientific management. Lygature assists the RSNN in identifying topics for scientific meetings, co-organizing the meetings, and ensuring that RSNN events lead to impactful outputs.
RSNN makes an important contribution to Lygature’s mission of accelerating the launch of new medicines for patients. The project has required extensive management capabilities, along with expertise in both science and the regulatory landscape.
Lygature together with
Regulatory Science Network Netherlands welcomes Marjon Pasmooij
RSNN welcomes Marjon Pasmooij as the latest member of its Steering Committee. We asked her to discuss how she sees the role of RSNN, and what challenges come next for regulatory science.
Save the date: RSNN workshop on 17 April 2019
The fourth edition of the RSNN workshop will take place on Wednesday 17 April 2019 from 13:00-21:00. This year’s topic will be “The future of clinical trials and evidence generation, and their use in regulatory decision making”.
Early stage cooperation between patients, developers, regulators and HTA bodies is critical for success in cancer treatment development
During the FIGON Dutch Medicines Days on October 1-2, the RSNN organized two regulatory science sessions around novel cancer treatments and the associated regulatory challenges. We look back at engaging presentations and discussions with a large, varied group of stakeholders.